ARCA biopharma Files Shelf Registration Statement
April 04 2014 - 3:05PM
Business Wire
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular
diseases, today announced that it has filed a universal shelf
registration statement with the Securities and Exchange Commission
(SEC) that, if declared effective by the SEC, will allow the
Company to sell, from time to time, up to $75 million of its common
stock, preferred stock, depository shares, debt securities and/or
warrants in one or more offerings. As of the date of this release,
the Company has no specific plans to offer the securities covered
by the registration statement and the Company is not required to
offer the securities in the future pursuant to the registration
statement.
The terms of any offering under the registration statement will
be established at the time of the offering. Proceeds from the sale
of any securities will be used for the purposes described in a
prospectus supplement filed at the time of an offering. If and when
the SEC declares this registration statement effective, the Company
intends to retire the unused portion of its previous shelf
registration statement that was declared effective by the SEC on
April 4, 2011 and is expiring.
A shelf registration statement relating to these securities was
filed today with the SEC but has not yet become effective. Any
securities offered by the Company pursuant to the registration
statement may not be sold, nor may offers to buy the securities be
accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy, nor shall there be any sale
of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such
jurisdiction.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted
therapies for cardiovascular diseases. The Company's lead product
candidate, GencaroTM (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild
vasodilator being developed for atrial fibrillation. ARCA has
identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to
be the first genetically-targeted atrial fibrillation prevention
treatment. ARCA has a collaboration with Medtronic, Inc. for
support of the GENETIC-AF trial. For more information please visit
www.arcabiopharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements include, but are
not limited to, statements regarding, potential for any future
offering of securities, potential timing for any securities
offerings, and the sufficiency of the Company’s capital to support
its operations, the potential for genetic variations to predict
individual patient response to Gencaro, Gencaro’s potential to
treat atrial fibrillation, and the potential for Gencaro to be the
first genetically-targeted atrial fibrillation prevention
treatment. Such statements are based on management's current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with:
the Company's financial resources and whether they will be
sufficient to meet the Company's business objectives and
operational requirements; results of earlier clinical trials may
not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process;
and, the impact of competitive products and technological changes.
These and other factors are identified and described in more detail
in ARCA’s filings with the SEC, including without limitation the
Company’s annual report on Form 10-K for the year ended December
31, 2013, and subsequent filings. The Company disclaims any intent
or obligation to update these forward-looking statements.
ARCA biopharma, Inc.Investor & Media
Contact:Derek Cole,
720-940-2163derek.cole@arcabiopharma.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2024 to May 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From May 2023 to May 2024